CHEK1 and neoplasm: To further confirm effectiveness, one of these compounds, prexasertib (a CHK1 inhibitor), was tested for its anti-tumor effects in a subcutaneous transplantation model using Sph18–02, which was resistant to gemcitabine treatment in the xenograft model.